Seres Therapeutics
MCRB · Nasdaq · United States
Share price · MCRB
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when MCRB's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 9 Nov 2026-14.1%
Nothing announced by MCRB that day or the session before.
- 29 Oct 2026+8.9%
Nothing announced by MCRB that day or the session before.
- 27 Oct 2026-9.1%
- 1 Oct 2026-12.5%
Nothing announced by MCRB that day or the session before.
- 16 Sep 2026-8.5%
Nothing announced by MCRB that day or the session before.
- 8 Jul 2026-12.3%
- 29 Jun 2026+10.0%
Nothing announced by MCRB that day or the session before.
- 12 Jun 2026-9.8%
Nothing announced by MCRB that day or the session before.
- 4 Jun 2026-4.5%
Nothing announced by MCRB that day or the session before.
- 1 Jun 2026+4.4%
Share of unusual movement by asset
For each asset, the share of MCRB's own-move activity since 3 Sep 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
SER-155events and moves
| 2 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 2% |
| Other company news (earnings, financing, releases naming no asset) | — | 7% |
| Sessions with no dated event | — | 91% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 1 | Gut microbiome (cultivated bacterial consortium)Microbiome therapeutic | Graft-versus-Host Disease Bacterial Infections in Allogeneic Stem Cell Transplant |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $0.6M | $5.6M | $21M | $16M-$10M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $0.7M | $9.1M | $18M | —-$22M operating cash flow | report ↗ |
| 2026-Q1 | $0.4M | $13M | $39M | $20M-$16M operating cash flow | report ↗ |
| 2025-Q3 | $0.3M | $13M | $56M | —$2.2M operating cash flow | report ↗ |
| 2025-Q2 | $0 | $13M | $54M | $20M-$13M operating cash flow | report ↗ |
| 2025-Q1 | $0 | $12M | $68M | —$27M operating cash flow | report ↗ |
| 2024-Q3 | $0 | $16M | $77M | —-$35M operating cash flow | report ↗ |
| 2024-Q2 | $0 | $18M | $81M | $33M-$40M operating cash flow | report ↗ |
| 2024-Q1 | $0 | $22M | $120M | $40M-$35M operating cash flow | report ↗ |
| 2023-Q3 | $0.3M | $28M | $178M+ $0 short-term inv. | $48M-$59M operating cash flow | report ↗ |
| 2023-Q2 | $126M | $47M | $238M+ $0 short-term inv. | —$66M operating cash flow | report ↗ |
| 2023-Q1 | -$0.5M | $44M | $103M+ $12M short-term inv. | $71M-$77M operating cash flow | report ↗ |
| 2022-Q3 | $3.4M | $43M | $214M+ $28M short-term inv. | $60M-$60M operating cash flow | report ↗ |
| 2022-Q2 | $1.2M | $44M | $135M+ $69M short-term inv. | $65M-$50M operating cash flow | report ↗ |
| 2022-Q1 | $1.5M | $40M | $161M+ $95M short-term inv. | $57M-$66M operating cash flow | report ↗ |
| 2021-Q3 | $127M | $40M | $227M+ $120M short-term inv. | —$128M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $0.8M | $49M | $54M | —$1.1M operating cash flow | report ↗ |
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $0 | $65M | $39M | —-$149M operating cash flow | report ↗ |
| 2023-FY | $126M | $146M | $136M+ $0 short-term inv. | $28M-$117M operating cash flow | report ↗ |
| 2022-FY | $7.1M | $173M | $171M+ $18M short-term inv. | $63M-$229M operating cash flow | report ↗ |
| 2021-FY | $145M | $142M | $188M+ $111M short-term inv. | $16M$6.7M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 16 sales ($11K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-16 | Henn Matthew R · See Remarks | Open-market sale | 101 | $1.38 | $139 | Form 4 |
| 2026-11-16 | Shaff Eric D. · director | Open-market sale | 287 | $1.38 | $396 | Form 4 |
| 2026-11-16 | DesRosier Thomas · See Remarks | Open-market sale | 103 | $1.38 | $142 | Form 4 |
| 2026-11-16 | Brady Kelly · See Remarks | Open-market sale | 85 | $1.38 | $117 | Form 4 |
| 2026-11-15 | Henn Matthew R · See Remarks | Option exercise | 238 | — | — | Form 4 |
| 2026-11-15 | Shaff Eric D. · director | Option exercise | 724 | — | — | Form 4 |
| 2026-11-15 | DesRosier Thomas · See Remarks | Option exercise | 244 | — | — | Form 4 |
| 2026-11-15 | Brady Kelly · See Remarks | Option exercise | 181 | — | — | Form 4 |